Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Metastasis | Research

Differential presence of exons (DPE): sequencing liquid biopsy by NGS. A new method for clustering colorectal Cancer patients

Authors: David Rubio-Mangas, Mariano García-Arranz, Yaima Torres-Rodriguez, Miguel León-Arellano, Javier Suela, Damián García-Olmo

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Differential presence of exons (DPE) by next generation sequencing (NGS) is a method of interpretation of whole exome sequencing. This method has been proposed to design a predictive and diagnostic algorithm with clinical value in plasma from patients bearing colorectal cancer (CRC). The aim of the present study was to determine a common exonic signature to discriminate between different clinical pictures, such as non-metastatic, metastatic and non-disease (healthy), using a sustainable and novel technology in liquid biopsy.
Through DPE analysis, we determined the differences in DNA exon levels circulating in plasma between patients bearing CRC vs. healthy, patients bearing CRC metastasis vs. non-metastatic and patients bearing CRC metastasis vs. healthy comparisons. We identified a set of 510 exons (469 up and 41 down) whose differential presence in plasma allowed us to group and classify between the three cohorts. Random forest classification (machine learning) was performed and an estimated out-of-bag (OOB) error rate of 35.9% was obtained and the predictive model had an accuracy of 75% with a confidence interval (CI) of 56.6–88.5.
In conclusion, the DPE analysis allowed us to discriminate between different patho-physiological status such as metastatic, non-metastatic and healthy donors. In addition, this analysis allowed us to obtain very significant values with respect to previous published results, since we increased the number of samples in our study. These results suggest that circulating DNA in patient’s plasma may be actively released by cells and may be involved in intercellular communication and, therefore, may play a pivotal role in malignant transformation (genometastasis).
Appendix
Available only for authorised users
Literature
15.
go back to reference Pastor B, André T, Henriques J, Trouilloud I, Tournigand C, Jary M, et al. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal Cancer as a potential biomarker of responses to Regorafenib treatment. Mol Oncol. 2021;15(9):2401–11. https://doi.org/10.1002/1878-0261.12972.CrossRef Pastor B, André T, Henriques J, Trouilloud I, Tournigand C, Jary M, et al. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal Cancer as a potential biomarker of responses to Regorafenib treatment. Mol Oncol. 2021;15(9):2401–11. https://​doi.​org/​10.​1002/​1878-0261.​12972.CrossRef
16.
go back to reference van Helden EJ, Angus L, der Houven M-v, van Oordt CW, Heideman DAM, Boon E, et al. RAS and BRAF mutations in cell-free DNA are predictive for outcome of Cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal Cancer. Mol Oncol. 2019;13(11):2361–74. https://doi.org/10.1002/1878-0261.12550.CrossRef van Helden EJ, Angus L, der Houven M-v, van Oordt CW, Heideman DAM, Boon E, et al. RAS and BRAF mutations in cell-free DNA are predictive for outcome of Cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal Cancer. Mol Oncol. 2019;13(11):2361–74. https://​doi.​org/​10.​1002/​1878-0261.​12550.CrossRef
17.
go back to reference Vitiello PP, De Falco V, Giunta EF, Ciardiello D, Cardone C, Vitale P, et al. Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal Cancer (MCRC): a single institution experience. Cancers (Basel). 2019;11(10):E1504. https://doi.org/10.3390/cancers11101504.CrossRef Vitiello PP, De Falco V, Giunta EF, Ciardiello D, Cardone C, Vitale P, et al. Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal Cancer (MCRC): a single institution experience. Cancers (Basel). 2019;11(10):E1504. https://​doi.​org/​10.​3390/​cancers11101504.CrossRef
20.
go back to reference Olmedillas-López S, García-Olmo DC, García-Arranz M, Peiró-Pastor R, Aguado B, García-Olmo D. Liquid biopsy by NGS: differential presence of exons (DPE) in cell-free DNA reveals different patterns in metastatic and nonmetastatic colorectal Cancer. Cancer Medicine. 2018;7(5):1706–16. https://doi.org/10.1002/cam4.1399.CrossRef Olmedillas-López S, García-Olmo DC, García-Arranz M, Peiró-Pastor R, Aguado B, García-Olmo D. Liquid biopsy by NGS: differential presence of exons (DPE) in cell-free DNA reveals different patterns in metastatic and nonmetastatic colorectal Cancer. Cancer Medicine. 2018;7(5):1706–16. https://​doi.​org/​10.​1002/​cam4.​1399.CrossRef
Metadata
Title
Differential presence of exons (DPE): sequencing liquid biopsy by NGS. A new method for clustering colorectal Cancer patients
Authors
David Rubio-Mangas
Mariano García-Arranz
Yaima Torres-Rodriguez
Miguel León-Arellano
Javier Suela
Damián García-Olmo
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-022-10459-w

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine